The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Open accessAbstract
BACKGROUNDTezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell-derived cytokine implicated in the pathogenesis of asthma.The efficacy and safety of tezepelumab in patients with severe, uncontrolled asthma require further assessment. METHODSWe conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.Patients (12 to 80 years of age) were randomly assigned to receive tezepelumab (210 mg) or placebo subcutaneously every 4 weeks for 52 weeks.The primary end point was the annualized rate of asthma exacerbations over a period of 52 weeks.This end point was also assessed in patients with baseline blood eosinophil counts of less than 300 cells per microliter.Secondary end points included the forced expiratory volume in 1 second (FEV 1 ) and scores on the Asthma Control Questionnaire-6 (ACQ-6; range, 0 [no impairment] to 6 [maximum impairment]), Asthma Quality of Life Questionnaire (AQLQ; range, 1 [maximum impairment] to 7 [no impairment]), and Asthma Symptom Diary (ASD; range, 0 [no symptoms] to 4 [worst possible symptoms]). RESULTSOverall, 1061 patients underwent randomization (529 were assigned to receive tezepelumab and 532 to receive placebo).The annualized rate of asthma exacerbations was 0.93 (95% confidence interval [CI], 0.80 to 1.07) with tezepelumab and 2.10 (95% CI, 1.84 to 2.39) with placebo (rate ratio, 0.44; 95% CI, 0.37 to 0.53; P<0.001).In patients with a blood eosinophil count of less than 300 cells per microliter, the annualized rate was 1.02 (95% CI, 0.84 to 1.23) with tezepelumab and 1.73 (95% CI, 1.46 to 2.05) with placebo (rate ratio, 0.59; 95% CI, 0.46 to 0.75; P<0.001).At week 52, improvements were greater with tezepelumab than with placebo with respect to the prebronchodilator FEV 1 (0.23 vs. 0.09 liters; difference, 0.13 liters; 95% CI, 0.08 to 0.18; P<0.001) and scores on the ACQ-6 (-1.55 vs. -1.22;difference, -0.33; 95% CI, -0.46 to -0.20; P<0.001), AQLQ (1.49 vs. 1.15; difference, 0.34; 95% CI, 0.20 to 0.47; P<0.001), and ASD (-0.71 vs. -0.59;difference, -0.12; 95% CI, -0.19 to -0.04; P = 0.002).The frequencies and types of adverse events did not differ meaningfully between the two groups. CONCLUSIONSPatients with severe, uncontrolled asthma who received tezepelumab had fewer exacerbations and better lung function, asthma control, and health-related quality of life than those who received placebo.(Funded by AstraZeneca and Amgen; NAVIGATOR ClinicalTrials.govnumber, NCT03347279.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986
Self-citationBleecker, E. R., FitzGerald, J. M., Chanez, P., Papi, A., Weinstein, S. F., Barker, P., Sproule, S., Gilmartin, G., Aurivillius, M., Werkström, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31324-1 · Cited by 1,406
FitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G. T., Busse, W. W., Barker, P., Sproule, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31322-8 · Cited by 1,397
Tezepelumab in Adults with Uncontrolled Asthma
Corren, J., Parnes, J. R., Wang, L., Mo, M., Roseti, S. L., Griffiths, J. M., & van der Merwe, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704064 · Cited by 965
Self-citationEffects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
Gauvreau, G. M., O'Byrne, P. M., Boulet, L.-P., Wang, Y., Cockcroft, D., Bigler, J., FitzGerald, J. M., Boedigheimer, M., Davis, B. E., Dias, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402895 · Cited by 789
Allakhverdi, Z., Comeau, M. R., Jessup, H. K., Yoon, B.-R. P., Brewer, A., Chartier, S., Paquette, N., Ziegler, S. F., Sarfati, M., & Delespesse, G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062211 · Cited by 786
Validation of a Standardized Version of the Asthma Quality of Life Questionnaire
Juniper, E. F., Buist, A. S., Cox, F. M., Ferrie, P. J., & King, D. R. (1999) · Chest · doi:10.1378/chest.115.5.1265 · Cited by 714
Ortega, H. G., Yancey, S. W., Mayer, B., Gunsoy, N. B., Keene, O. N., Bleecker, E. R., Brightling, C. E., & Pavord, I. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30031-5 · Cited by 559
Self-citationEosinophilic and Noneosinophilic Asthma
Carr, T. F., Zeki, A. A., & Kraft, M. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201611-2232pp · Cited by 351
Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma
Shikotra, A., Choy, D. F., Ohri, C. M., Doran, E., Butler, C., Hargadon, B., Shelley, M., Abbas, A. R., Austin, C. D., Jackman, J., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.08.031 · Cited by 333
Liu, S., Verma, M., Michalec, L., Liu, W., Sripada, A., Rollins, D., Good, J., Ito, Y., Chu, H., Gorska, M. M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.03.032 · Cited by 303
TSLP enhances the function of helper type 2 cells
Kitajima, M., Lee, H., Nakayama, T., & Ziegler, S. F. (2011) · European Journal of Immunology · doi:10.1002/eji.201041195 · Cited by 235
Treatment options in type-2 low asthma
Hinks, T. S. C., Levine, S. J., & Brusselle, G. G. (2021) · European Respiratory Journal · doi:10.1183/13993003.00528-2020 · Cited by 187
Asthma outcomes: Pulmonary physiology
Tepper, R. S., Wise, R. S., Covar, R., Irvin, C. G., Kercsmar, C. M., Kraft, M., Liu, M. C., O'Connor, G. T., Peters, S. P., Sorkness, R., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.12.986 · Cited by 177
Tanaka, J., Watanabe, N., Kido, M., Saga, K., Akamatsu, T., Nishio, A., & Chiba, T. (2008) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03151.x · Cited by 160
Menzies-Gow, A. N., Colice, G., Griffiths, J. M., Almqvist, G., Ponnarambil, S. S., Kaur, P. P., Ruberto, G., Bowen, K., Hellqvist, Å., Mo, M. F., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01526-6 · Cited by 142
Self-citationChen, S. H., Golam, S. M., Myers, J. A., Bly, C. A., Smolen, H. J., & Xu, X. P. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1505352 · Cited by 113
Liang, Y., Yu, B., Chen, J., Wu, H., Xu, Y., Yang, B., & Lu, Q. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.06.011 · Cited by 73
Allakhverdi, Z., Comeau, M. R., Jessup, H. K., & Delespesse, G. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.01.059 · Cited by 65
A TSLP-complement axis mediates neutrophil killing of methicillin-resistant Staphylococcus aureus
West, E. E., Spolski, R. J., Kazemian, M., Yu, Z., Kemper, C., & Leonard, W. J. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8471 · Cited by 55
Symptoms and markers of symptom severity in asthma—content validity of the asthma symptom diary
Globe, G. A., Martin, M. L., Schatz, M. X., Wiklund, I. E., Lin, J., von Maltzahn, R., & Mattera, M. S. (2015) · Health and Quality of Life Outcomes · doi:10.1186/s12955-015-0217-5 · Cited by 53
Ly, N. S., Zheng, Y., Griffiths, J. M., van der Merwe, R., Agoram, B. M., Parnes, J. R., & Roskos, L. K. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1803 · Cited by 30
Self-citationCorren, J., Gil, E. G., Parnes, J. R., et al. (2019) · doi:10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2621 · Cited by 19
Self-citationGlobe, G. A., Wiklund, I. E., Lin, J., Chen, W.-H., Martin, M. L., Mattera, M. S., von Maltzahn, R., Feng, J., Chon, Y., Viswanathan, H. N., et al. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.07.008 · Cited by 18
Globe, G. A., Wiklund, I. E., Mattera, M. S., Zhang, H., & Revicki, D. A. (2019) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-019-0109-2 · Cited by 17
Cited by
Biologic Therapies for Severe Asthma
Brusselle, G. G., & Koppelman, G. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032506 · Cited by 715
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
Stolz, D., Mkorombindo, T., Schumann, D. M., Agusti, A., Ash, S. Y., Bafadhel, M., Bai, C., Chalmers, J. D., Criner, G. J., Dharmage, S. C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01273-9 · Cited by 681
Pathogenesis of allergic diseases and implications for therapeutic interventions
Wang, J., Zhou, Y., Zhang, H., Hu, L., Liu, J., Wang, L., Wang, T., Zhang, H., Cong, L., & Wang, Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01344-4 · Cited by 376
Miller, R. L., Grayson, M. H., & Strothman, K. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.10.001 · Cited by 365
Kaplon, H., Chenoweth, A., Crescioli, S., & Reichert, J. M. (2022) · mAbs · doi:10.1080/19420862.2021.2014296 · Cited by 331
Metadata
- Authors
- Menzies-Gow, A., Corren, J., Bourdin, A., Chupp, G., Israel, E., Wechsler, M. E., Brightling, C. E., Griffiths, J. M., Hellqvist, Å., Bowen, K., Kaur, P., Almqvist, G., Ponnarambil, S., & Colice, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-13
- Volume
- 384
- Issue
- 19
- Pages
- 1800-1809
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3162024685
- Cited by
- 1,056
- References
- 27
- FWCI
- 83.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.